Ulka Vaishampayan MD, FASCO, MBBS

Dr. Ulka Vaishampayan is the Director of the Phase I program at the Rogel Cancer Center, University of Michigan, Ann Arbor, MI. Dr. Vaishampayan is a Professor of Internal Medicine, and her research is primarily in translational drug development and early-phase clinical trials in cancer with a focus on genitourinary malignancies. She has initiated, obtained funding for, and conducted and published many investigator-initiated trials with embedded biomarkers and established multidisciplinary collaboration.

She has served as site PI of the UO-1 Early Therapeutics Research Grant at Wayne State University. She was also the chair of the solid tumor division of oncology at WSU. She has completed a formal leadership training course and is a Fellow of the Advisory Board (FAB). She is the appointed chair of the Advanced Renal committee of SWOG and a member of the Renal task force of the NCI. She is a board member of the Michigan Society of Hematology/Oncology (MSHO) and organizes an annual board review course. Additionally, she has served as track leader for the ASCO education committee GU non-prostate (Renal and bladder cancer) track.

Dr. Vaishampayan attended Wayne State University for her residency and fellowship completion, attended medical school at Byramjee Jeejeebhoy in Pune, India, and completed a higher secondary certificate in the field of science at Fergusson College in Pune, India.